[Pubmed] Nipocalimab: First Approval

[RSS-Bot]

Drugs. 2025 Aug 8. doi: 10.1007/s40265-025-02211-y. Online ahead of print.

ABSTRACT

Nipocalimab (nipocalimab-aahu; IMAAVY™) is a fully human monoclonal antibody that binds to and blocks the neonatal fragment crystallizable (Fc) receptor (FcRn) resulting in the reduction of circulating IgG levels. It is being developed by Johnson & Johnson for the treatment of a number of autoimmune disorders. On 29 April 2025, nipocalimab received its first approval in the USA for the treatment of generalized myasthenia gravis in adult and pediatric patients ≥ 12 years of age who are anti-acetylcholine receptor or anti-muscle specific tyrosine kinase antibody positive. Regulatory review of nipocalimab is underway for generalized myasthenia gravis in Japan and the European Union. This article summarizes the milestones in the development of nipocalimab leading to this first approval for generalized myasthenia gravis.

PMID:40779124 | DOI:10.1007/s40265-025-02211-y


Source: https://pubmed.ncbi.nlm.nih.gov/4077912 ... t9+e462414